Observational studyClinical drug investigation2019
Gut Microbiome in Psoriasis is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to Treatment.
Observational study in Clinical drug investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- The Emerging Role of Gut Microbiota in Inflammatory Skin Diseases: A Systematic Review.Experimental dermatology · 2026Pooled it
- Characterization of the Gut Microbiota in Patients with Psoriasis: A Systematic Review.Pathogens (Basel, Switzerland) · 2025Pooled it
- Characterization of the Oral and Gut Microbiota in Patients with Psoriatic Diseases: A Systematic Review.Acta dermato-venereologica · 2021Pooled it
- Pharmacomicrobiomics in Psoriasis: Microbiome-Drug Interactions Across Systemic Treatments.Life (Basel, Switzerland) · 2026Review
- Akkermansia Muciniphila Ameliorates Imiquimod-Induced Skin Thickening, Colitis, and Gut Microbiota Alterations: A Metagenome Association Study.Inflammation · 2026Article
- Psoriasis: microbiome dysbiosis and pathogenic mechanisms.Frontiers in immunology · 2026Review
- Probiotics and Diet in Rosacea: Current Evidence and Future Perspectives.Biomolecules · 2025Review
- Review
- Psoriasis and gut microbes: research advances from mechanism to therapy.Frontiers in microbiology · 2025Review
- Pharmacomicrobiomics in inflammatory skin diseases: past, present, and the future.Frontiers in microbiology · 2025Review
- The complex interplay between psoriasis and depression: from molecular mechanisms to holistic treatment approaches.Frontiers in immunology · 2025Review
- The Contribution of the Skin Microbiome to Psoriasis Pathogenesis and Its Implications for Therapeutic Strategies.Medicina (Kaunas, Lithuania) · 2024Review
- The Role of Gut Microbiota in the Efficacy and Side Effect Profile of Biologic Therapies for Autoimmune Diseases.Cureus · 2024Review
- The failure of biological treatment in axial spondyloarthritis is linked to the factors related to increased intestinal permeability and dysbiosis: prospective observational cohort study.Rheumatology international · 2024Observational
- Short-chain fatty acids ameliorate imiquimod-induced skin thickening and IL-17 levels and alter gut microbiota in mice: a metagenomic association analysis.Scientific reports · 2024Article
- Metagenomics reveals unique gut mycobiome biomarkers in psoriasis.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- Observational
- IL-17A inhibitors alleviate Psoriasis with concomitant restoration of intestinal/skin microbiota homeostasis and altered microbiota function.Frontiers in immunology · 2024Article
- Gut microbiota and psoriasis: pathogenesis, targeted therapy, and future directions.Frontiers in cellular and infection microbiology · 2024Review
- Investigating causal associations among gut microbiota, metabolites, and psoriatic arthritis: a Mendelian randomization study.Frontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
objectiveImmunotherapy could change the complex host-microbial interactions. We aimed to investigate the dynamics of gut microbiome in response to secukinumab [an interleukin (IL)-17 inhibitor] and ustekinumab (an IL-12/23 inhibitor) therapy and its association with treatment response in psoriasis.
methodsThis observational, longitudinal study collected a total of 114 fecal samples from 12 healthy controls and 34 patients with psoriasis at baseline and 3 and 6 months after secukinumab (n = 24) or ustekinumab treatment (n = 10) and gut microbiomes were investigated using next-generation sequencing targeting 16S ribosomal RNA.
resultsSecukinumab treatment causes more profound alterations in gut microbiome, including increases in the relative abundance of phylum Proteobacteria and decreases in Bacteroidetes and Firmicutes, than ustekinumab treatment. The relative abundance of family Pseudomonadaceae, family Enterobacteriaceae and order Pseudomonadales also increased significantly following secukinumab therapy. In contrast, there was no significant change in gut microbiome composition following ustekinumab treatment, and only genus Coprococcus significantly increased after 6 months of ustekinumab therapy. Moreover, we observed significant differences in baseline gut microbiome between responders and non-responders to secukinumab treatment.
conclusionThese results indicate that gut microbiome is altered differently after anti-IL17 and anti-IL12/23 treatment. Secukinumab (anti-IL17) therapy is associated with distinct and more profound gut microbiome shifts than ustekinumab therapy (anti-IL 12/23) in patients with psoriasis. Moreover, gut microbiome would serve as potential biomarkers of response to secukinumab treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.